Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!

USFDA warning letter to Lupin on Somerset facility cites repeated GMP violations at manufacturing network

"Repeated violations at multiple sites demonstrate your company’s corporate oversight and control over the manufacture of drugs is inadequate," the USFDA said in the letter addressed to Vinita Gupta, CEO of Lupin

June 30, 2021 / 04:23 PM IST
In its warning letter USFDA pointed out three major violations of current good manufacturing practices (cGMP) at Somerset site

In its warning letter USFDA pointed out three major violations of current good manufacturing practices (cGMP) at Somerset site

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

The USFDA, in a warning letter on June 11 to Lupin on the company’s Somerset facility in New Jersey, has cited repeated violations at the company's manufacturing facilities.

“Repeated violations at multiple sites demonstrate that your company’s corporate oversight and control over the manufacture of drugs is inadequate," USFDA said in the letter addressed to Vinita Gupta, CEO of Lupin.

“You should further comprehensively assess your company’s global manufacturing operations to ensure that systems and processes, and ultimately, the drug products manufactured, conform to FDA requirements at all your sites,” the letter said.

Please read here for more on the warning letter.

Somerset cGMP violations

Close

In its warning letter, the USFDA pointed out three major violations of current good manufacturing practices (cGMP) at the Somerset site. They include the firm's failure to establish and follow adequate written procedures over cleaning and maintenance of equipment. USFDA expressed concern that the deficiencies in cleaning procedures may lead to cross-contamination.

The second major issue was the firm's failure to establish adequate written procedures for production and process control, designed to assure that the drug products the company manufacture have the identity, strength, quality, and purity they purport or are represented to possess.

The third one was the failure to establish and follow adequate written responsibilities and procedures applicable to the quality control unit.

USFDA asked Lupin to test all reserve samples of drug products within the expiry date and released to the US market, which were manufactured on the tablet press that was found wanting in cleaning norms. In addition, the agency asked for a comprehensive and independent retrospective assessment of cleaning effectiveness to evaluate the scope of cross-contamination hazards.

The USFDA also sought a detailed summary of validation programme for ensuring a state of control throughout the product lifecycle, along with associated procedures.

“Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other federal agencies from awarding contracts,” the USFDA said.Lupin has 15 days to respond to the USFDA in writing.



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jun 30, 2021 10:14 am
Sections
ISO 27001 - BSI Assurance Mark